Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Ph I/II Nivolumab in comb w/ Lenalidomide in relapsed/refractory NHL and HD

Protocol: OSU-16167

Full Title

A Phase I/II Study of the PD-1 Antibody Nivolumab in combination with Lenalidomide in relapsed/refractory Non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s Disease (HD)

Lymphoma Non-Hodgkin’s Lymphoma (B- & T-Cell) Hodgkin’s Lymphoma